PetMed Express Net Income From Continuing Ops Over Time
| PETS Stock | USD 2.98 0.11 3.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PetMed Express Performance and PetMed Express Correlation. Is there potential for Other Specialty Retail market expansion? Will PetMed introduce new products? Factors like these will boost the valuation of PetMed Express. Anticipated expansion of PetMed directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about PetMed Express listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.667 | Earnings Share (2.56) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of PetMed Express is measured differently than its book value, which is the value of PetMed that is recorded on the company's balance sheet. Investors also form their own opinion of PetMed Express' value that differs from its market value or its book value, called intrinsic value, which is PetMed Express' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because PetMed Express' market value can be influenced by many factors that don't directly affect PetMed Express' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PetMed Express' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PetMed Express should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PetMed Express' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare PetMed Express and related stocks such as Cytosorbents Crp, Icecure Medical, and Tela Bio Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTSO | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (9.3 M) | (9.5 M) | (11.9 M) | (8.5 M) | (17.2 M) | (19.3 M) | (7.8 M) | (24.6 M) | (32.8 M) | (28.5 M) | (20.7 M) | (18.6 M) | (19.6 M) |
| ICCM | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (13.3 M) | (16.5 M) | (15.1 M) | (9.9 M) | (17 M) | (14.7 M) | (15.3 M) | (13.8 M) | (14.5 M) |
| TELA | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.3 M) | (21.1 M) | (22.4 M) | (28.8 M) | (33.3 M) | (44.3 M) | (43.8 M) | (37.8 M) | (34.1 M) | (35.8 M) |
| RNTX | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (26.2 M) | (27.3 M) | (15.7 M) | (62.8 M) | (56.5 M) | (53.7 M) |
| MDAI | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (2.9 M) | (20.9 M) | (15.3 M) | (13.8 M) | (14.5 M) |
| GNTA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (5.6 M) | (5.5 M) | (8.5 M) | (11.6 M) | (8.9 M) | (8 M) | (8.4 M) |
| BDSX | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (30.7 M) | (31.4 M) | (43.2 M) | (65.4 M) | (63.3 M) | (42.9 M) | (38.6 M) | (40.6 M) |
| FBIO | (27.6 M) | (27.6 M) | (27.6 M) | (20.4 M) | (20.4 M) | (53.9 M) | (71.3 M) | (99.8 M) | (130.8 M) | (101.7 M) | (103 M) | (164.8 M) | (213.9 M) | (182.6 M) | (120.9 M) | (108.8 M) | (114.2 M) |
| YI | (363.4 M) | (363.4 M) | (363.4 M) | (363.4 M) | (363.4 M) | (363.4 M) | (363.4 M) | (249.3 M) | (382 M) | (501.8 M) | (467.1 M) | (621 M) | (376.1 M) | (252.3 M) | (20.8 M) | (23.9 M) | (25.1 M) |
PetMed Express and related stocks such as Cytosorbents Crp, Icecure Medical, and Tela Bio Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| PetMed Express | PETS |
| Classification | Trump Equities |
| Business Address | 420 South Congress |
| Exchange | NASDAQ Exchange |
USD 2.98
Additional Tools for PetMed Stock Analysis
When running PetMed Express' price analysis, check to measure PetMed Express' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PetMed Express is operating at the current time. Most of PetMed Express' value examination focuses on studying past and present price action to predict the probability of PetMed Express' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PetMed Express' price. Additionally, you may evaluate how the addition of PetMed Express to your portfolios can decrease your overall portfolio volatility.